587 related articles for article (PubMed ID: 17472422)
1. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies.
Wernicke J; Lledó A; Raskin J; Kajdasz DK; Wang F
Drug Saf; 2007; 30(5):437-55. PubMed ID: 17472422
[TBL] [Abstract][Full Text] [Related]
2. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia.
Welsch P; Üçeyler N; Klose P; Walitt B; Häuser W
Cochrane Database Syst Rev; 2018 Feb; 2(2):CD010292. PubMed ID: 29489029
[TBL] [Abstract][Full Text] [Related]
3. Duloxetine: a dual reuptake inhibitor.
Dugan SE; Fuller MA
Ann Pharmacother; 2004 Dec; 38(12):2078-85. PubMed ID: 15522980
[TBL] [Abstract][Full Text] [Related]
4. Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome.
Häuser W; Urrútia G; Tort S; Uçeyler N; Walitt B
Cochrane Database Syst Rev; 2013 Jan; (1):CD010292. PubMed ID: 23440848
[TBL] [Abstract][Full Text] [Related]
5. Safety and tolerability of duloxetine in elderly patients with major depressive disorder: a pooled analysis of two placebo-controlled studies.
Oakes TM; Katona C; Liu P; Robinson M; Raskin J; Greist JH
Int Clin Psychopharmacol; 2013 Jan; 28(1):1-11. PubMed ID: 23138680
[TBL] [Abstract][Full Text] [Related]
6. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor.
Westanmo AD; Gayken J; Haight R
Am J Health Syst Pharm; 2005 Dec; 62(23):2481-90. PubMed ID: 16303903
[TBL] [Abstract][Full Text] [Related]
7. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range.
Mallinckrodt CH; Prakash A; Andorn AC; Watkin JG; Wohlreich MM
J Psychiatr Res; 2006 Jun; 40(4):337-48. PubMed ID: 16271726
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine and other antidepressants in the treatment of patients with fibromyalgia.
Arnold LM
Pain Med; 2007 Sep; 8 Suppl 2():S63-74. PubMed ID: 17714117
[TBL] [Abstract][Full Text] [Related]
9. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia.
Lunn MP; Hughes RA; Wiffen PJ
Cochrane Database Syst Rev; 2014 Jan; 2014(1):CD007115. PubMed ID: 24385423
[TBL] [Abstract][Full Text] [Related]
10. A retrospective pooled analysis of duloxetine safety in 23,983 subjects.
Gahimer J; Wernicke J; Yalcin I; Ossanna MJ; Wulster-Radcliffe M; Viktrup L
Curr Med Res Opin; 2007 Jan; 23(1):175-84. PubMed ID: 17257478
[TBL] [Abstract][Full Text] [Related]
11. Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study.
Maund E; Tendal B; Hróbjartsson A; Lundh A; Gøtzsche PC
BMJ; 2014 Jun; 348():g3555. PubMed ID: 24899651
[TBL] [Abstract][Full Text] [Related]
12. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: a pooled analysis.
Lam RW; Lönn SL; Despiégel N
Int Clin Psychopharmacol; 2010 Jul; 25(4):199-203. PubMed ID: 20357664
[TBL] [Abstract][Full Text] [Related]
13. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults.
Mariappan P; Ballantyne Z; N'Dow JM; Alhasso AA
Cochrane Database Syst Rev; 2005 Jul; (3):CD004742. PubMed ID: 16034945
[TBL] [Abstract][Full Text] [Related]
14. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder.
Hunziker ME; Suehs BT; Bettinger TL; Crismon ML
Clin Ther; 2005 Aug; 27(8):1126-43. PubMed ID: 16199241
[TBL] [Abstract][Full Text] [Related]
15. Duloxetine: a review of its use in the treatment of generalized anxiety disorder.
Carter NJ; McCormack PL
CNS Drugs; 2009; 23(6):523-41. PubMed ID: 19480470
[TBL] [Abstract][Full Text] [Related]
16. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial.
Millard RJ; Moore K; Rencken R; Yalcin I; Bump RC;
BJU Int; 2004 Feb; 93(3):311-8. PubMed ID: 14764128
[TBL] [Abstract][Full Text] [Related]
17. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder.
Bech P; Kajdasz DK; Porsdal V
Psychopharmacology (Berl); 2006 Oct; 188(3):273-80. PubMed ID: 16960699
[TBL] [Abstract][Full Text] [Related]
18. [Duloxetine, a new therapeutic option for diabetic peripheral neuropathic pain].
Ziegler D
Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S284-8. PubMed ID: 17139588
[TBL] [Abstract][Full Text] [Related]
19. Safety and adverse event profile of duloxetine.
Wernicke JF; Gahimer J; Yalcin I; Wulster-Radcliffe M; Viktrup L
Expert Opin Drug Saf; 2005 Nov; 4(6):987-93. PubMed ID: 16255658
[TBL] [Abstract][Full Text] [Related]
20. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications.
Maund E; Tendal B; Hróbjartsson A; Jørgensen KJ; Lundh A; Schroll J; Gøtzsche PC
BMJ; 2014 Jun; 348():g3510. PubMed ID: 24899650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
